Primary Open-angle Glaucoma Clinical Trial
Official title:
Multicentric Observational Clinical Study on Quality of Life in Patients With Glaucoma in Italy
The study aims to evaluate the quality of life (QoL) of patients affected by Primary
Open-Angle Glaucoma (POAG), using 2 QoL questionnaires:
1. Glaucoma Symptom Scale (GSS) and
2. National Eye Institute Visual Function Questionnaire (NEI-VFQ -25). The study will be
conducted on patients with well known diagnosis of POAG (transversal phase) and on
patients with first diagnosis of POAG (longitudinal phase).
The study provides two levels of investigation, the first one (transversal phase), for all
patients enrolled in the participating centers and the second one (longitudinal phase)
conducted in a single cohort of patients with new diagnosis of POAG at enrollment.
The study will take part in around 20 centers specialized in glaucoma treatment and care,
distributed throughout the Italian country area. The study aims to recruit a total of 3000
patients, around 200 of which with early diagnosis: they will represent the longitudinal
cohort.
The frequency of visits and the type of examinations will follow the normal clinical
practice.
The transversal phase consists of a single visit in which all socio-demographic and clinical
characteristics of patients will be collected; during this visit patients will receive the
NEI-VFQ 25 and the GSS questionnaires for measuring QoL (they have be filled in by the
patient himself). For newly diagnosed patients, data collected during this visit will be
consider as baseline, then they will enter in the longitudinal phase and will underwent two
subsequent visits, the first one after about 6 months from baseline and the second one after
a further 6 months (12 months from baseline). During the two subsequent visits the same data
as the baseline will be collected, excluding for the socio-demographic data.
Patients will underwent examinations and therapy suitable for their disease treatment, based
on physician judgment and according to the normal clinical practice.
All patient data will be collected on Case Report Form(CRF). All data contained in the CRF
and in the QoL questionnaires, will be entered into an electronic database and will be
checked in order to assess the plausibility, internal consistencies, errors or missing
values. For each missing/loose/illegible/wrong data a request for clarification will be
automatically generated by the system; it will be named "Query Form" and will be sent to the
investigator for answers. At the end of the validation process, the database will be
"frozen" and it will be used for statistical analysis.
The data were collected in an absolutely anonymous way. No data can be traced back up to the
patient personal information or history.
All patients enrolled in the study, except for those with inclusion/exclusion criteria
violations, will be considered in the statistical analysis.
The general characteristics of the study sample will be described. Qualitative variables
will be described by means of the absolute and relative frequencies calculation, those
quantitative with mean, standard deviation, quartiles, minimum, maximum, number of
observations.
With regard to the QoL scale, the total score and subscale will be calculated. The same
approach will be used within subgroups defined on the basis of socio-demographic and
clinical characteristics.
As per the calculation of the sample size, it is estimated that at present in Italy there
are 500,000 patients affected by glaucoma and about 50 centers specialized in the disease
treatment.
A sample of 3000 patients with POAG and the involvement of at least 20 centers specialized
in the glaucoma treatment are considered to be a representative estimation of reality in the
Italian coutry area.
With a sample size of at least 3000 patients it is possible to calculate the 95%confidence
interval of the estimated value of any parameter collected with an inaccuracy who not exceed
3.6%.
It is assumed that it will be possible to isolate about 200 patients in first diagnosis, in
which the time course of the QOL scales scores will be described for the entire cohort and
into predetermined patient subgroups.
For a successful implementation of the procedures required by the study the following
activities are provided:
- Start-up and follow-up meetings, with the aim of sharing operating procedures, training
the investigators to use the study tools for the collection of data and following-up
study issues;
- Project dedicated Help Desk.
This study will be conducted according to AIFA March 20, 2008, "Guidelines for the
classification and management of observational studies on drugs" and the principles
expressed in the guidelines for the 'Good Epidemiology Practice' (GEP) in force in Europe.
A patient's informed consent and a consent to the processing of their data, signed by each
patient, will be obtained before the study entry.
;
Observational Model: Cohort
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01841437 -
Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry
|
N/A | |
Completed |
NCT02077231 -
Study of Vitamin A and Carbomer in Comforting the Ocular Surface Irritations of Glaucoma Patients
|
N/A | |
Completed |
NCT01410188 -
Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
|
Phase 1/Phase 2 | |
Recruiting |
NCT05557058 -
GORE Glaucoma Drainage Implant Clinical Study
|
N/A | |
Not yet recruiting |
NCT03924544 -
Decorin in Sub Scleral Trabeculectomy
|
Phase 1 | |
Active, not recruiting |
NCT03673644 -
Impact of Glaucoma and Visual Field Loss on Life Space
|
||
Completed |
NCT03365778 -
Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment
|
N/A | |
Completed |
NCT01915940 -
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 2 | |
Completed |
NCT03889652 -
Optical Coherence Tomography of Nerve Fiber Layer and Ganglion Cell Complex After Cataract Extraction
|
||
Terminated |
NCT03273907 -
Post Approval Study of the CyPass System
|
N/A | |
Recruiting |
NCT03193333 -
PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)
|
Phase 3 | |
Recruiting |
NCT03921931 -
Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot Study
|
N/A | |
Not yet recruiting |
NCT04609345 -
Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients
|
||
Recruiting |
NCT05264818 -
Assessment of Endothelial Glycocalyx in Patients With Primary Open-angle Glaucoma
|
||
Completed |
NCT04333433 -
PRESERFLO® MicroShunt Extension Study
|
||
Enrolling by invitation |
NCT02144103 -
Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration
|
Phase 1/Phase 2 | |
Completed |
NCT01281020 -
Adherence With Fixed Versus Unfixed Glaucoma Therapy
|
||
Recruiting |
NCT04891588 -
Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD
|
N/A | |
Completed |
NCT03145129 -
PAIR Study-PAP And IOP Relationship: Study 2
|
||
Completed |
NCT03104621 -
Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients
|
Phase 4 |